_id
6913130accc777a4e85d7f73
Ticker
MAZE
Name
Maze Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
171 Oyster Point Blvd, South San Francisco, CA, United States, 94080
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.mazetx.com
Description
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Last Close
40.86
Volume
432094
Current Price
40.32
Change
-1.66
Last Updated
2026-01-05T10:08:38.516Z
Image
data:image/webp;base64,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
Ipo Date
2025-01-31T00:00:00.000Z
Market Cap
1913710336
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
4.75
Target Price
46.5556
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
32965000
Operating Income
-32965000
Interest Expense
-
Pretax Income
-30087000
Net Income
-30087000
Eps
-0.6572144605005852
Dividends Per Share
-
Shares Outstanding
48119444
Income Tax Expense
-
EBITDA
-29516000
Operating Margin
-
Total Other Income Expense Net
2878000
Cash
316773000
Short Term Investments
67162000
Receivables
700000
Inventories
-
Total Current Assets
391302000
Property Plant Equipment
26458000
Total Assets
422058000
Payables
2918000
Short Term Debt
4764000
Long Term Debt
-
Total Liabilities
42622000
Equity
379436000
Bs_currency_symbol
USD
Depreciation
571000
Change In Working Capital
2463000
Cash From Operations
-24642000
Capital Expenditures
68000
Cash From Investing
-66883000
Cash From Financing
143757000
Net Change In Cash
52232000
Cf_currency_symbol
USD
PE
-
PB
4.864674265594198
ROE
-7.929400478605088
ROA
-7.128641087243934
FCF
-24710000
Fcf Percent
-
Piotroski FScore
1
Health Score
38
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
32965000
Quarters > 0 > income Statement > operating Income
-32965000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-30087000
Quarters > 0 > income Statement > net Income
-30087000
Quarters > 0 > income Statement > eps
-0.6572144605005852
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
45779577
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-29516000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
2878000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
316773000
Quarters > 0 > balance Sheet > short Term Investments
67162000
Quarters > 0 > balance Sheet > receivables
700000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
391302000
Quarters > 0 > balance Sheet > property Plant Equipment
26458000
Quarters > 0 > balance Sheet > total Assets
422058000
Quarters > 0 > balance Sheet > payables
2918000
Quarters > 0 > balance Sheet > short Term Debt
4764000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
42622000
Quarters > 0 > balance Sheet > equity
379436000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-30087000
Quarters > 0 > cash Flow > depreciation
571000
Quarters > 0 > cash Flow > change In Working Capital
2463000
Quarters > 0 > cash Flow > cash From Operations
-24642000
Quarters > 0 > cash Flow > capital Expenditures
68000
Quarters > 0 > cash Flow > cash From Investing
-66883000
Quarters > 0 > cash Flow > cash From Financing
143757000
Quarters > 0 > cash Flow > net Change In Cash
52232000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.6572144605005852
Quarters > 0 > ratios > PB
4.864674265594198
Quarters > 0 > ratios > ROE
-7.929400478605088
Quarters > 0 > ratios > ROA
-7.128641087243934
Quarters > 0 > ratios > FCF
-24710000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
38
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
649000
Quarters > 1 > income Statement > gross Profit
-649000
Quarters > 1 > income Statement > operating Expenses
35825000
Quarters > 1 > income Statement > operating Income
-36474000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-33679000
Quarters > 1 > income Statement > net Income
-33679000
Quarters > 1 > income Statement > eps
-0.7680346877385642
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
43850884
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-33030000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
2795000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
264541000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
271150000
Quarters > 1 > balance Sheet > property Plant Equipment
27713000
Quarters > 1 > balance Sheet > total Assets
303519000
Quarters > 1 > balance Sheet > payables
3666000
Quarters > 1 > balance Sheet > short Term Debt
4718000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
41281000
Quarters > 1 > balance Sheet > equity
262238000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-33679000
Quarters > 1 > cash Flow > depreciation
649000
Quarters > 1 > cash Flow > change In Working Capital
-1038000
Quarters > 1 > cash Flow > cash From Operations
-30052000
Quarters > 1 > cash Flow > capital Expenditures
393000
Quarters > 1 > cash Flow > cash From Investing
-393000
Quarters > 1 > cash Flow > cash From Financing
612000
Quarters > 1 > cash Flow > net Change In Cash
-29833000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.7680346877385642
Quarters > 1 > ratios > PB
6.742225165231584
Quarters > 1 > ratios > ROE
-12.84291368909159
Quarters > 1 > ratios > ROA
-11.09617519825777
Quarters > 1 > ratios > FCF
-30445000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
684000
Quarters > 2 > income Statement > gross Profit
-684000
Quarters > 2 > income Statement > operating Expenses
35401000
Quarters > 2 > income Statement > operating Income
-35401000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-32786000
Quarters > 2 > income Statement > net Income
-32786000
Quarters > 2 > income Statement > eps
-0.7485872487731284
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
43797166
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-34717000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
2615000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
294374000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
299707000
Quarters > 2 > balance Sheet > property Plant Equipment
28797000
Quarters > 2 > balance Sheet > total Assets
332840000
Quarters > 2 > balance Sheet > payables
2404000
Quarters > 2 > balance Sheet > short Term Debt
4674000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
40772000
Quarters > 2 > balance Sheet > equity
292068000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-32786000
Quarters > 2 > cash Flow > depreciation
684000
Quarters > 2 > cash Flow > change In Working Capital
-1425000
Quarters > 2 > cash Flow > cash From Operations
-29516000
Quarters > 2 > cash Flow > capital Expenditures
299000
Quarters > 2 > cash Flow > cash From Investing
-299000
Quarters > 2 > cash Flow > cash From Financing
127378000
Quarters > 2 > cash Flow > net Change In Cash
97563000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.7485872487731284
Quarters > 2 > ratios > PB
6.046200655737705
Quarters > 2 > ratios > ROE
-11.225468041688922
Quarters > 2 > ratios > ROA
-9.8503785602692
Quarters > 2 > ratios > FCF
-29815000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
705000
Quarters > 3 > income Statement > gross Profit
-705000
Quarters > 3 > income Statement > operating Expenses
29726000
Quarters > 3 > income Statement > operating Income
-29726000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-29854000
Quarters > 3 > income Statement > net Income
-29579000
Quarters > 3 > income Statement > eps
-0.6753804343619335
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
43796057
Quarters > 3 > income Statement > income Tax Expense
-275000
Quarters > 3 > income Statement > EBITDA
-29021000
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-128000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
196812000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
201671000
Quarters > 3 > balance Sheet > property Plant Equipment
29918000
Quarters > 3 > balance Sheet > total Assets
240542000
Quarters > 3 > balance Sheet > payables
1939000
Quarters > 3 > balance Sheet > short Term Debt
4632000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
43638000
Quarters > 3 > balance Sheet > equity
196904000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-29579000
Quarters > 3 > cash Flow > depreciation
705000
Quarters > 3 > cash Flow > change In Working Capital
1031000
Quarters > 3 > cash Flow > cash From Operations
-22452000
Quarters > 3 > cash Flow > capital Expenditures
605000
Quarters > 3 > cash Flow > cash From Investing
-605000
Quarters > 3 > cash Flow > cash From Financing
70262000
Quarters > 3 > cash Flow > net Change In Cash
47205000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.6753804343619335
Quarters > 3 > ratios > PB
8.968111456547353
Quarters > 3 > ratios > ROE
-15.022041197741032
Quarters > 3 > ratios > ROA
-12.296813030572624
Quarters > 3 > ratios > FCF
-23057000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
35
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
167500000
Annuals > 0 > income Statement > cost Of Revenue
3297000
Annuals > 0 > income Statement > gross Profit
167500000
Annuals > 0 > income Statement > operating Expenses
109914000
Annuals > 0 > income Statement > operating Income
57586000
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
53403000
Annuals > 0 > income Statement > net Income
52231000
Annuals > 0 > income Statement > eps
1.1925959453381842
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
43796057
Annuals > 0 > income Statement > income Tax Expense
1172000
Annuals > 0 > income Statement > EBITDA
60883000
Annuals > 0 > income Statement > operating Margin
34.379701492537315
Annuals > 0 > income Statement > total Other Income Expense Net
-4183000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
196812000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
201671000
Annuals > 0 > balance Sheet > property Plant Equipment
29918000
Annuals > 0 > balance Sheet > total Assets
240542000
Annuals > 0 > balance Sheet > payables
1939000
Annuals > 0 > balance Sheet > short Term Debt
4632000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
43638000
Annuals > 0 > balance Sheet > equity
196904000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
52231000
Annuals > 0 > cash Flow > depreciation
3297000
Annuals > 0 > cash Flow > change In Working Capital
-1523000
Annuals > 0 > cash Flow > cash From Operations
75954000
Annuals > 0 > cash Flow > capital Expenditures
1147000
Annuals > 0 > cash Flow > cash From Investing
-1147000
Annuals > 0 > cash Flow > cash From Financing
92847000
Annuals > 0 > cash Flow > net Change In Cash
167654000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
1.1925959453381842
Annuals > 0 > ratios > PB
8.845778586976396
Annuals > 0 > ratios > ROE
26.52612440580181
Annuals > 0 > ratios > ROA
21.713879488821078
Annuals > 0 > ratios > FCF
74807000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.4466089552238806
Annuals > 0 > health Score
86
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
4089000
Annuals > 1 > income Statement > gross Profit
-4089000
Annuals > 1 > income Statement > operating Expenses
98551000
Annuals > 1 > income Statement > operating Income
-98551000
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-100415000
Annuals > 1 > income Statement > net Income
-100415000
Annuals > 1 > income Statement > eps
-2.293785560072237
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
43776978
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-94462000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-1864000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
29158000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
34110000
Annuals > 1 > balance Sheet > property Plant Equipment
34984000
Annuals > 1 > balance Sheet > total Assets
71504000
Annuals > 1 > balance Sheet > payables
2019000
Annuals > 1 > balance Sheet > short Term Debt
4489000
Annuals > 1 > balance Sheet > long Term Debt
20080000
Annuals > 1 > balance Sheet > total Liabilities
61450000
Annuals > 1 > balance Sheet > equity
10054000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-100415000
Annuals > 1 > cash Flow > depreciation
4089000
Annuals > 1 > cash Flow > change In Working Capital
-6316000
Annuals > 1 > cash Flow > cash From Operations
-86827000
Annuals > 1 > cash Flow > capital Expenditures
441000
Annuals > 1 > cash Flow > cash From Investing
-441000
Annuals > 1 > cash Flow > cash From Financing
16385000
Annuals > 1 > cash Flow > net Change In Cash
-70883000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-2.293785560072237
Annuals > 1 > ratios > PB
173.16594540083548
Annuals > 1 > ratios > ROE
-998.7567137457729
Annuals > 1 > ratios > ROA
-140.43270306556278
Annuals > 1 > ratios > FCF
-87268000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
9
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
3820000
Annuals > 2 > income Statement > gross Profit
-3820000
Annuals > 2 > income Statement > operating Expenses
111026000
Annuals > 2 > income Statement > operating Income
-111026000
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-114940000
Annuals > 2 > income Statement > net Income
-114940000
Annuals > 2 > income Statement > eps
-2.625580961755743
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
43776978
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-107206000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-3914000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
99919000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
106149000
Annuals > 2 > balance Sheet > property Plant Equipment
41228000
Annuals > 2 > balance Sheet > total Assets
149957000
Annuals > 2 > balance Sheet > payables
1585000
Annuals > 2 > balance Sheet > short Term Debt
4324000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
48514000
Annuals > 2 > balance Sheet > equity
101443000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-114940000
Annuals > 2 > cash Flow > depreciation
3820000
Annuals > 2 > cash Flow > change In Working Capital
-3236000
Annuals > 2 > cash Flow > cash From Operations
-99203000
Annuals > 2 > cash Flow > capital Expenditures
1966000
Annuals > 2 > cash Flow > cash From Investing
-3170000
Annuals > 2 > cash Flow > cash From Financing
1728000
Annuals > 2 > cash Flow > net Change In Cash
-100645000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-2.625580961755743
Annuals > 2 > ratios > PB
17.162449997141252
Annuals > 2 > ratios > ROE
-113.30500872411106
Annuals > 2 > ratios > ROA
-76.64863927659262
Annuals > 2 > ratios > FCF
-101169000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
27
Valuation > metrics > PE
-0.6572144605005852
Valuation > metrics > PB
4.864674265594198
Valuation > final Score
31.35325734405802
Valuation > verdict
62.2% Overvalued
Profitability > metrics > ROE
-7.929400478605088
Profitability > metrics > ROA
-7.688946133676803
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.11232987908369264
Risk > metrics > Interest Coverage
-57.73204903677758
Risk > final Score
-171
Risk > verdict
High
Liquidity > metrics > Current Ratio
50.93751627180422
Liquidity > metrics > Quick Ratio
50.93751627180422
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-165
Prev Risks > 1
-13
Prev Risks > 2
-83
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:10:50.458Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-06
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.66
Earnings History > 0 > eps Estimate
-0.62
Earnings History > 0 > eps Difference
-0.04
Earnings History > 0 > surprise Percent
-6.4516
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-12
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.77
Earnings History > 1 > eps Estimate
-0.62
Earnings History > 1 > eps Difference
-0.15
Earnings History > 1 > surprise Percent
-24.1935
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-15
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-1.15
Earnings History > 2 > eps Estimate
-0.6263
Earnings History > 2 > eps Difference
-0.5237
Earnings History > 2 > surprise Percent
-83.6181
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-31
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-18.32
Earnings History > 3 > eps Estimate
0.45
Earnings History > 3 > eps Difference
-18.77
Earnings History > 3 > surprise Percent
-4171.1111
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AFirst Week of March 20th Options Trading For Maze Therapeutics (MAZE) Nasdaq
Read more →Maze Therapeutics (NASDAQ:MAZE) Reaches New 1-Year High - What's Next? MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$46.5556
Analyst Picks
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
0
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Maze Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.66
EPS Estimate
-0.62
EPS Difference
-0.04
Surprise Percent
-6.4516%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.